Skip to main content

OCUL

Stock
Health Care
Biotechnology

Performance overview

OCUL Price
Price Chart

Forward-looking statistics

Beta
1.39
Risk
70.19%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Company info

SectorHealth Care
IndustryBiotechnology
Employees270
Market cap$765.2M

Fundamentals

Enterprise value$1.2B
Revenue$59.6M
Revenue per employee—
Profit margin91.17%
Debt to equity28.66

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.11
Dividend per share—
Revenue per share$0.36
Avg trading volume (30 day)$29M
Avg trading volume (10 day)$30M
Put-call ratio—

Macro factor sensitivity

Growth+3.2
Credit+6.1
Liquidity+1.2
Inflation0.0
Commodities-1.3
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-9.43
Price to sales25.69
P/E Ratio-9.43
Enterprise Value to Revenue20.20
Price to book5.76

Upcoming events

Next earnings dayMay 5, 2025
Next dividend day—
Ex. dividend day—

News

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Investment Research (June 25, 2025)
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company's lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD).

Benzinga (March 11, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free